Celltrion Healthcare is a leading Korean biopharmaceutical company that specialises in biosimilars. Celltrion developed the world’s first biosimilar monoclonal antibody, which led to a paradigm shift in the global biopharmaceutical market. Biosimilars from Celltrion contribute to reducing global healthcare costs, which allows for the reinvestment of saved healthcare resources into patient care around the world. Celltrion is not just a biosimilar company, but also an innovative pharmaceutical company that strives for novel solutions such as subcutaneous formulations for intravenously administered monoclonal antibody therapies.